Yikaida® Marks Five Years Since Launch: A Milestone Journey of China's CAR-T Therapy from 0 to 1

Jun 26, 2026 18:12 CST Updated 18:12

Fosun Kairos

Developer of Tumor Immune Cell Therapy Technologies and Products

In June 2026, Fosun Kairos, the cell therapy technology platform under Fosun Pharma, launched its first CAR-T drug, Yikaida^®(Yescarta injection) celebrates its fifth anniversary since market launch. On June 22, 2021, Yikaida^®Its market approval officially ushered in the inaugural year of CAR-T therapy in China, marking a breakthrough from “0” to “1” in the domestic cell therapy sector, bringing hope to more patients, and leading the high-quality development of lymphoma treatment in China.

Yikaida, China's First CAR-T Cell Therapy Product®Since its market launch, it has achieved comprehensive and synergistic breakthroughs across multiple dimensions—including clinical value, treatment networks, and indication expansion—driven by verifiable real-world efficacy and consistent pharmaceutical quality control.

Continuous Validation of Clinical Value:

Cumulatively treated over 1,500 patients with relapsed/refractory lymphoma; Aunt Qin, the first CAR-T patient in China, has achieved cancer-free survival for more than eight years while maintaining complete remission. In June 2023, Yikaida®New Indication Approved for Market Launch (Adult Large B-Cell Lymphoma Refractory to First-Line Immunochemotherapy or Relapsing Within 12 Months After First-Line Immunochemotherapy)

Nationwide Treatment Network Coverage:

Fosun Kairos has successfully established over 200 Yikaida centers across 29 provinces (autonomous regions, and municipalities) in China.®High-Standard Treatment Centers: Patients Can Access High-Quality CAR-T Therapy Services Locally, Significantly Enhancing Healthcare Convenience and Treatment Accessibility.

Accelerated Advancement of R&D Pipeline:

Yikaida®The third indication (for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma [r/r iNHL]) is in the bridging clinical trial phase in China and has been included in the Breakthrough Therapy Drug Program by the Center for Drug Evaluation of the National Medical Products Administration.

Zhang Wenjie

Co-President of Fosun Pharma

Chairman of Fosun Kairos

Yikaida^®Its growth vividly embodies Fosun Pharma’s brand philosophy of “Continuous Innovation, Joyful Health,” and concretely realizes the corporate mission of “Enabling Every Family to Enjoy Health.” Consistently, Fosun Pharma has integrated ESG principles across its entire industry chain, setting a benchmark for sustainable development among Chinese pharmaceutical enterprises through pragmatic actions. As the core platform for cell therapy within Fosun Pharma and a leading enterprise in China’s cell therapy sector, Fosun Kairos will continue to embed social responsibility into its corporate strategy and operations, steadily enhancing the accessibility of high-quality innovative medicines, and fulfilling its responsibilities as an industry leader.

Yikaida®The past five years have witnessed the deep translation of science into clinical practice and continuous breakthroughs in the accessibility of innovative therapies. From the first patient treated to a collaborative medical network spanning over 200 treatment centers across China, and from innovative explorations in outcomes-based payment to inclusion in the national commercial insurance directory... Throughout these five years, Fosun Kairos has remained steadfastly patient-centric, ensuring that every treatment carries the weight of life.

Looking ahead, Fosun Kairos will uphold its corporate mission of “Focused on Cures, Illuminating Lives,” persist in independent R&D, and build a robust product pipeline. While continuously consolidating its leadership in hematologic malignancies, the company will further expand into solid tumors, autoimmune diseases, and various cutting-edge innovative technology platforms. It will advance the R&D of pipelines such as in vivo CAR-T and CAR-NK therapies, driving cell therapy from the laboratory to clinical reality. Striving to become the most valuable leader in cell and gene therapies, Fosun Kairos aims to ensure that Chinese innovations benefit more lives worldwide.

Contact Information

Media:pr@fosunpharma.com

Investors:ir@fosunpharma.com